Yahoo Finance Insiders who bought into Axsome Therapeutics, Inc. (NASDAQ:AXSM) earlier this year might wish they'd invested more as stock gained 9.8%
Last week, Axsome Therapeutics, Inc. (NASDAQ:AXSM) insiders, who had purchased shares in the previous 12 months were rewarded handsomely. The shares increased by 9.8% last week, resulting in a US$127m increase in the company's market worth. In other words, the original US$374k purchase is now worth US$384k.
Although we don't think shareholders should simply follow insider transactions, logic dictates you should pay some attention to whether insiders are buying or selling shares.
Check out our latest analysis for Axsome Therapeutics
The Last 12 Months Of Insider Transactions At Axsome Therapeutics
Notably, that recent purchase by Roger Jeffs is the biggest insider purchase of Axsome Therapeutics shares that we've seen in the last year. That implies that an insider found the current price of US$37.93 per share to be enticing. Of course they may have changed their mind. But this suggests they are optimistic. While we always like to see insider buying, it's less meaningful if the purchases were made at much lower prices, as the opportunity they saw may have passed. The good news for Axsome Therapeutics share holders is that insiders were buying at near the current price.
In the last twelve months Axsome Therapeutics insiders were buying shares, but not selling. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
Axsome Therapeutics is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
Axsome Therapeutics Insiders Bought Stock Recently
It's good to see that Axsome Therapeutics insiders have made notable investments in the company's shares. In total, insiders bought US$345k worth of shares in that time, and we didn't record any sales whatsoever. That shows some optimism about the company's future.
Insider Ownership of Axsome Therapeutics
I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. We usually like to see fairly high levels of insider ownership. Insiders own 1.9% of Axsome Therapeutics shares, worth about US$27m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.
So What Do The Axsome Therapeutics Insider Transactions Indicate?
It's certainly positive to see the recent insider purchases. And the longer term insider transactions also give us confidence. But we don't feel the same about the fact the company is making losses. Given that insiders also own a fair bit of Axsome Therapeutics we think they are probably pretty confident of a bright future. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. For instance, we've identified 3 warning signs for Axsome Therapeutics (1 is a bit unpleasant) you should be aware of.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
